Skip to main content
Top
Published in: BMC Neurology 1/2022

Open Access 01-12-2022 | Myasthenia Gravis | Research

Myasthenia gravis - a retrospective analysis of e-mail inquiries made to a patient organisation and specialized center to uncover unmet needs from patients and caregivers

Authors: Maike Stein, Sarah Hoffmann, Lea Gerischer, Frauke Stascheit, David Legg, Andreas Meisel, Sophie Lehnerer

Published in: BMC Neurology | Issue 1/2022

Login to get access

Abstract

Background and aims

Myasthenia Gravis requires expert treatment from specialized neurologists. In Germany, this treatment is mainly provided by 18 Integrated Myasthenia Centers (iMZ) accredited by the German Myasthenia Gravis Association (DMG). The DMG is a large and well-organized patient organisation that is regarded as a trusted source for disease-specific information. The aim of this study was to analyse the type of requests that each of these institutions receives in order to identify any potential unmet needs regarding the availability of advice for patients and caregivers. This data can then be used in further research to tailor modern digital communication tools to the specific needs of MG patients.

Methods

Counselling requests sent via e-mail to both institutions were extracted for defined examination periods and divided into a period ‘before COVID-19 pandemic’ (01.07.2019–31.12.2019) and ‘during COVID-19 pandemic’ (01.07.2020–31.12.2020). Requests were then analysed using four main categories: medical requests, organisational issues, COVID-19 and social legislation inquiries.

Results

One thousand seven hundred eleven requests for advice were addressed to DMG and iMZ Charité. Most inquiries directed to the DMG (47%; n = 750) were related to medical issues, most frequently to side effects of medications (n = 325; 20%) and questions about treatment (n = 263; 16%), followed by inquiries regarding organisational issues (26%; n = 412). About half of the inquiries (n = 69; 58%) to the iMZ Charité were related to medical issues and almost one in three inquiries concerned organisational issues (n = 37; 30%). About one in ten inquiries concerned socio-legal matters (iMZ: n = 7; 6% and DMG: n = 177; 11%). During the pandemic, COVID-19 related issues accounted for 8% (n = 6) of inquiries at iMZ, and 16% (n = 253) at DMG.

Conclusions

MG sufferers have a high demand for timely advice. In the current setting, they address their requests to both iMZs and the DMG via e-mail. Our findings confirm that the DMG is highly trusted by patients and caregivers and is used to obtain second opinions. A relevant proportion of requests to the iMZ could be answered more effectively through standardized responses or improved process management. The implementation of modern digital solutions, including telemedicine, for communication between patient and specialist should be evaluated in further research.
Appendix
Available only for authorised users
Literature
1.
go back to reference Huijbers MG, Marx A, Plomp JJ, Le Panse R, Phillips WD. Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022;21(2):163–75.CrossRef Huijbers MG, Marx A, Plomp JJ, Le Panse R, Phillips WD. Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022;21(2):163–75.CrossRef
2.
go back to reference Verschuuren JJ, Palace J, Murai H, Tannemaat MR, Kaminski HJ, Bril V. Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022;21(2):189–202.CrossRef Verschuuren JJ, Palace J, Murai H, Tannemaat MR, Kaminski HJ, Bril V. Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022;21(2):189–202.CrossRef
3.
go back to reference Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30.CrossRef Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30.CrossRef
4.
go back to reference Bungard S, Rohn H, Dobler K. Certification of myasthenia centres: developing and implementing a certification procedure for patient organisations. Z Evid Fortbild Qual Gesundhwes. 2011;105(1):49–53.CrossRef Bungard S, Rohn H, Dobler K. Certification of myasthenia centres: developing and implementing a certification procedure for patient organisations. Z Evid Fortbild Qual Gesundhwes. 2011;105(1):49–53.CrossRef
5.
go back to reference Lehnerer S, Jacobi J, Schilling R, Grittner U, Marbin D, Gerischer L, et al. Burden of disease in myasthenia gravis: taking the patient's perspective. J Neurol, 269(6):3050–63. Lehnerer S, Jacobi J, Schilling R, Grittner U, Marbin D, Gerischer L, et al. Burden of disease in myasthenia gravis: taking the patient's perspective. J Neurol, 269(6):3050–63.
6.
go back to reference Boldingh MI, Dekker L, Maniaol AH, Brunborg C, Lipka AF, Niks EH, et al. An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts. Health Qual Life Outcomes. 2015;13:115.CrossRef Boldingh MI, Dekker L, Maniaol AH, Brunborg C, Lipka AF, Niks EH, et al. An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts. Health Qual Life Outcomes. 2015;13:115.CrossRef
7.
go back to reference Jeong A, Min JH, Kang YK, Kim J, Choi M, Seok JM, et al. Factors associated with quality of life of people with myasthenia gravis. PLoS One. 2018;13(11):e0206754.CrossRef Jeong A, Min JH, Kang YK, Kim J, Choi M, Seok JM, et al. Factors associated with quality of life of people with myasthenia gravis. PLoS One. 2018;13(11):e0206754.CrossRef
8.
go back to reference Boscoe AN, Xin H, L'Italien GJ, Harris LA, Cutter GR. Impact of refractory myasthenia gravis on health-related quality of life. J Clin Neuromuscul Dis. 2019;20(4):173–81.CrossRef Boscoe AN, Xin H, L'Italien GJ, Harris LA, Cutter GR. Impact of refractory myasthenia gravis on health-related quality of life. J Clin Neuromuscul Dis. 2019;20(4):173–81.CrossRef
9.
go back to reference Padua L, Evoli A, Aprile I, Caliandro P, Mazza S, Padua R, et al. Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements. Neurol Sci. 2001;22(5):363–9.CrossRef Padua L, Evoli A, Aprile I, Caliandro P, Mazza S, Padua R, et al. Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements. Neurol Sci. 2001;22(5):363–9.CrossRef
10.
go back to reference Dong D, Chong MK, Wu Y, Kaminski H, Cutter G, Xu X, et al. Gender differences in quality of life among patients with myasthenia gravis in China. Health Qual Life Outcomes. 2020;18(1):296.CrossRef Dong D, Chong MK, Wu Y, Kaminski H, Cutter G, Xu X, et al. Gender differences in quality of life among patients with myasthenia gravis in China. Health Qual Life Outcomes. 2020;18(1):296.CrossRef
11.
go back to reference Ohlraun S, Hoffmann S, Klehmet J, Kohler S, Grittner U, Schneider A, et al. Impact of myasthenia gravis on family planning: how do women with myasthenia gravis decide and why? Muscle Nerve. 2015;52(3):371–9.CrossRef Ohlraun S, Hoffmann S, Klehmet J, Kohler S, Grittner U, Schneider A, et al. Impact of myasthenia gravis on family planning: how do women with myasthenia gravis decide and why? Muscle Nerve. 2015;52(3):371–9.CrossRef
12.
13.
go back to reference Abbas AS, Hardy N, Ghozy S, Dibas M, Paranjape G, Evanson KW, et al. Characteristics, treatment, and outcomes of myasthenia gravis in COVID-19 patients: a systematic review. Clin Neurol Neurosurg. 2022;213:107140.CrossRef Abbas AS, Hardy N, Ghozy S, Dibas M, Paranjape G, Evanson KW, et al. Characteristics, treatment, and outcomes of myasthenia gravis in COVID-19 patients: a systematic review. Clin Neurol Neurosurg. 2022;213:107140.CrossRef
14.
go back to reference Frost A, Svendsen ML, Rahbek J, Stapelfeldt CM, Nielsen CV, Lund T. Labour market participation and sick leave among patients diagnosed with myasthenia gravis in Denmark 1997-2011: a Danish nationwide cohort study. BMC Neurol. 2016;16(1):224.CrossRef Frost A, Svendsen ML, Rahbek J, Stapelfeldt CM, Nielsen CV, Lund T. Labour market participation and sick leave among patients diagnosed with myasthenia gravis in Denmark 1997-2011: a Danish nationwide cohort study. BMC Neurol. 2016;16(1):224.CrossRef
15.
go back to reference Blum S, Lee D, Gillis D, McEniery DF, Reddel S, McCombe P. Clinical features and impact of myasthenia gravis disease in Australian patients. J Clin Neurosci. 2015;22(7):1164–9.CrossRef Blum S, Lee D, Gillis D, McEniery DF, Reddel S, McCombe P. Clinical features and impact of myasthenia gravis disease in Australian patients. J Clin Neurosci. 2015;22(7):1164–9.CrossRef
16.
go back to reference Harris L, Aban IB, Xin H, Cutter G. Employment in refractory myasthenia gravis: a Myasthenia Gravis Foundation of America registry analysis. Muscle Nerve. 2019;60(6):700–6.CrossRef Harris L, Aban IB, Xin H, Cutter G. Employment in refractory myasthenia gravis: a Myasthenia Gravis Foundation of America registry analysis. Muscle Nerve. 2019;60(6):700–6.CrossRef
17.
go back to reference Twork S, Wiesmeth S, Klewer J, Pohlau D, Kugler J. Quality of life and life circumstances in German myasthenia gravis patients. Health Qual Life Outcomes. 2010;8:129.CrossRef Twork S, Wiesmeth S, Klewer J, Pohlau D, Kugler J. Quality of life and life circumstances in German myasthenia gravis patients. Health Qual Life Outcomes. 2010;8:129.CrossRef
18.
go back to reference Ricciardi D, Casagrande S, Iodice F, Orlando B, Trojsi F, Cirillo G, et al. Myasthenia gravis and telemedicine: a lesson from COVID-19 pandemic. Neurol Sci. 2021;42(12):4889–92.CrossRef Ricciardi D, Casagrande S, Iodice F, Orlando B, Trojsi F, Cirillo G, et al. Myasthenia gravis and telemedicine: a lesson from COVID-19 pandemic. Neurol Sci. 2021;42(12):4889–92.CrossRef
19.
go back to reference Guidon AC, Muppidi S, Nowak RJ, Guptill JT, Hehir MK, Ruzhansky K, et al. Telemedicine visits in myasthenia gravis: expert guidance and the myasthenia gravis Core exam (MG-CE). Muscle Nerve. 2021;64(3):270–6.CrossRef Guidon AC, Muppidi S, Nowak RJ, Guptill JT, Hehir MK, Ruzhansky K, et al. Telemedicine visits in myasthenia gravis: expert guidance and the myasthenia gravis Core exam (MG-CE). Muscle Nerve. 2021;64(3):270–6.CrossRef
Metadata
Title
Myasthenia gravis - a retrospective analysis of e-mail inquiries made to a patient organisation and specialized center to uncover unmet needs from patients and caregivers
Authors
Maike Stein
Sarah Hoffmann
Lea Gerischer
Frauke Stascheit
David Legg
Andreas Meisel
Sophie Lehnerer
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2022
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-022-02981-y

Other articles of this Issue 1/2022

BMC Neurology 1/2022 Go to the issue